5010-24-2

Usage

Derivative of ethanediamine

Ethylenediamine
The compound is derived from ethanediamine, which is a parent compound with two amine groups.

5-chloro-2-nitrophenyl group

Contains a chlorine atom at the 5th position and a nitro group at the 2nd position on a phenyl ring.
This group is a key structural feature of the compound, contributing to its chemical properties and reactivity.

Two methyl groups

N,N-dimethyl
The compound has two methyl groups attached to the nitrogen atoms, which can influence its reactivity and properties.

Applications

Dyes, pigments, pharmaceuticals, and agrochemicals
The compound is used as a raw material in the production of various products, indicating its versatility in different industries.

Intermediate in synthesis

Organic compounds
It serves as an intermediate in the synthesis of other organic compounds, highlighting its importance in chemical reactions.

Toxicity

Harmful if swallowed, inhaled, or absorbed through the skin
The compound is considered toxic, and proper safety measures should be taken when handling it to minimize exposure and potential health risks.

Safety measures

Necessary when handling
Due to its toxicity, it is crucial to follow safety protocols, such as wearing protective gear and working in a well-ventilated area, to minimize the risk of exposure.

Upstream product

• 700-37-8 4-chloro-2-fluoro-nitrobenzene 
• 108-00-9 N,N-dimethylethylenediamine 

Downstream Products

• 138423-14-0 N'-(5-Imidazol-1-yl-2-nitro-phenyl)-N,N-dimethyl-ethane-1,2-diamine 
• 1027495-00-6 N²-(2-Dimethylamino-ethyl)-4-imidazol-1-yl-benzene-1,2-diamine 

Relevant academic research and scientific papers

Novel AMPA receptor antagonists: Synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds

As part of our study of novel antagonists at the α-amino-3-hydroxy-5- methylisoxazole-4-propionate (AMPA) subtype of excitatory amino acid (EAA) receptors and the pharmacophoric requirements of the receptor, we designed and synthesized a series of 1-substituted 6-imidazolyl-7-nitro-, and 7- imidazolyl-6-nitroquinoxalinediones, as well as related compounds, 6a-j, 7, 11a-e, 15, and 17, which are 1- and 4-substituted analogues of 1 (YM90K), and evaluated their activity to inhibit [3H]AMPA binding from rat whole brain. On the basis of their structure-activity relationships (SAR), we deduced that the amide proton of the imidazolyl-near side of the quinoxalinedione nucleus is not essential for AMPA receptor binding, whereas that of the imidazolyl- far amide is. Further, the receptors possess size-limited bulk tolerance for their N-substituents on the imidazolyl-near amide portion. Moreover, we found that introduction of a hydroxyl group at the imidazolyl-near amide portion causes a severalfold improvement in AMPA receptor affinity over unsubstituted derivatives. Among the compounds, 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro- 2,3(1H,4H)-quinoxalinedione (11a) showed high affinity for AMPA receptor with a K(i) value of 0.021 μM, which is severalfold greater than that of 1 and NBQX (2) (1, K(i) = 0.084 μM; 2, K(i) = 0.060 μM). Compound 11a also showed over 100-fold selectivity for the AMPA receptor than for the N-methy]-D- aspartate (NMDA) receptor and the glycine site on NMDA receptor.